Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 1999

View Archived Issues

Sepracor's progress in third quarter

Italian laboratory designs new phototherapeutic/photodiagnostic compounds

Antisense oligonucleotides that modulate human HER-2 expression patented

Rhone-Poulenc and Hoechst present new Aventis logo

Second-generation virus from Calydon begins clinical testing in prostate cancer

Coactinon effective and safe as part of first-line protease inhibitor-sparing regimen

Tenofovir disoproxil fumarate: clinical activity correlated with intracellular levels

PDE4-inhbitory pyridines disclosed by Janssen

Warner-Lambert patents new anticoagulants with quinolinone structure

Improved muscarinic agents for cognitive disorders

HMR's newest antiresorptive compounds

Schering-Plough files for marketing clearance for desloratadine on two continents

Protein Design Labs and Roche expand Zenapax partnership

StessGen begins trial of HspE7 for anal dysplasia

Alza and Crescendo report efficacy data for once-daily ADD/ADHD therapy

Pivotal data presented for Celgene's ADD/ADHD therapy

Cubist receives further grant funding for antiinfective research

Antihypertensive agent unexpectedly found to hold potential as male contraceptive

News from ASRM/CFAS '99: Hughes Institute hones in on anti-HIV spermicides

Dramatic results described for STI-571 in CML patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...